| Similar Articles |
|---|
 |
The Motley Fool
December 20, 2004
Brian Gorman |
Cambridge Antibody's Underdog Story Cambridge Antibody's legal success against Abbott Laboratories is a sign of the biotech industry's continued maturation. Cambridge Antibody's stock rocketed 14% on the news of its win.   |
The Motley Fool
May 15, 2006
Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. |
Information Today
August 8, 2013 |
Cambridge Journals Online Enters API Beta Phase Cambridge Journals Online, released an API (application programming interface) so developers can use research data from all of the subjects CJO publishes in any software application they choose. |
Chemistry World
June 4, 2015
Phillip Broadwith |
Takeda to consolidate vaccines business in Boston Japanese pharma firm Takeda plans to close three US sites and move the headquarters of its vaccines business unit to the pharmaceutical hub in the Boston and Cambridge area of Massachusetts. |
Information Today
January 19, 2010 |
Cambridge University Press Launches New Ebook Platform More than 10,000 titles are expected to be available by spring 2010. With the launch of Cambridge Books Online, both frontlist and backlist content is now available to purchase for a single, one-off access fee, offering even more flexibility. |
Information Today
March 20, 2014 |
Cambridge University Press Plans New Database Cambridge University Press partnered with East View Information Services to build a fully searchable online platform for selling primary source research collections about regions in Asia. |
Financial Planning
January 1, 2010
Paul Menchaca |
Plains Vision Surrounded by nothing but miles of farmland are the offices of Cambridge Investment Research, a pioneer of the hybrid advisory model. |
Financial Planning
August 1, 2013
Ann Marsh |
Sharing the Load Cambridge founder CEO Eric Schwartz is making big plans to preserve the firm s independence and viability for the long term - by giving away control now. |
The Motley Fool
November 23, 2004
Brian Gorman |
AstraZeneca Buys Into Cambridge Antibody Cambridge Antibody scored a new alliance, although the deal threatens to make it a house divided. |
The Motley Fool
January 12, 2005
W.D. Crotty |
One Really Sorry IPO Cambridge Display Technology gets off to a bad start. For now the stock is for speculators who can afford to take a 100% loss. |
Bio-IT World
April 2006
Kevin Davies |
Bio*IT World's New Beginning Cambridge Healthtech Institute, along with its new acquisition of Bio*IT World, under the new name of Cambridge Bio Collaborative will become the key information and conference resource for the industry. |
Information Today
August 17, 2009 |
Cambridge University Press To Reissue Rare Books With POD Already a pioneer in the republishing of titles from its own backlist, Cambridge University Press is extending its reach to include other books of enduring scholarly value that are still of interest to researchers, students, and the general reader. |
The Motley Fool
March 10, 2006
Rich Smith |
Foolish Forecast: Cambridge Display Shows Off? Will there be anything to cheer about on Monday when cutting-edge display maker Cambridge Display reports fourth-quarter and full-year 2005 earnings. Investors, take note. |
Financial Planning
November 1, 2012 |
Calendar Technology tools for today... New york Consultants Conference... Fidelity urges Facebook users to look to the future... |
The Motley Fool
August 15, 2006
Anders Bylund |
Cambridge Display Lighting the Way A little-known company is changing the way we'll watch TV and light our homes. Investors, it's time to take note. |
IEEE Spectrum
June 2012
Prachi Patel |
The Benefits of MBAs in Europe Europe's top programs are less expensive and more worldly than U.S. counterparts |
Chemistry World
June 19, 2013
Laura Howes |
AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city. |
Chemistry World
March 19, 2013
Simon Hadlington |
Global AstraZeneca restructuring will cost 1600 jobs The company's global research blueprint will now be centered on the creation of three 'strategic R&D centers' for small molecules and biologics, to be based in Cambridge in the UK, Gaithersburg in Maryland, US, and Molndal in Sweden, to be completed by 2016. |
Information Today
October 12, 2008 |
University of Cambridge Teams Up With iTunes U Available to users worldwide, Cambridge's iTunes U channel features a variety of content from faculty members and other experts. |
